Compliance with AIM Rule 26

    YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26

    MISSISSAUGA, ON, Aug. 17 /CNW/ - YM BioSciences Inc. (AMEX:YMI, TSX:YM,
AIM:YMBA), an oncology company that identifies, develops and commercializes
differentiated products for patients worldwide, today announces that the
information required to be disclosed in accordance with Rule 26 of the AIM
Rules for Companies is available in the "Shareholder Information/Rule 26
Disclosures" section on the Company's home page, www.ymbiosciences.com.

    About YM BioSciences

    YM BioSciences Inc. is an oncology company that identifies, develops and
commercializes differentiated products for patients worldwide. The Company has
two late-stage products: nimotuzumab, a humanized monoclonal antibody that
targets the epidermal growth factor receptor (EGFR) for which recruitment in a
Phase III trial in pediatric glioma has just been completed and which is
approved in several countries for treatment of various types of head and neck
cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free
and liposome-encapsulated fentanyl in development for the treatment of
moderate to severe pain, including cancer pain.

    This press release may contain forward-looking statements, which reflect
the Company's current expectation regarding future events. These
forward-looking statements involve risks and uncertainties that may cause
actual results, events or developments to be materially different from any
future results, events or developments expressed or implied by such
forward-looking statements. Such factors include, but are not limited to,
changing market conditions, the successful and timely completion of clinical
studies, the establishment of corporate alliances, the impact of competitive
products and pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to time in the
Company's ongoing quarterly and annual reporting. Certain of the assumptions
made in preparing forward-looking statements include but are not limited to
the following: that nimotuzumab will continue to demonstrate a competitive
safety profile in ongoing and future clinical trials; that AeroLEF(TM) will
continue to generate positive efficacy and safety data in future clinical
trials; and that YM and its various partners will complete their respective
clinical trials within the timelines communicated in this release. We
undertake no obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events or
otherwise.

For further information: Thomas Fechtner, the Trout Group LLC, Tel. (212)
477-9007 x31, Fax [phone], Email: tfechtner(at)troutgroup.com; James
Smith, the Equicom Group Inc., Tel. [phone] x 229, Fax [phone],
Email: jsmith(at)equicomgroup.com; Nominated Adviser: Ryan Gaffney, Canaccord
Adams Ltd, Tel. [phone]
(YM. YMI)



END